Ikena Capital Surpluse vs Total Liab Analysis
| IKNA Stock | USD 1.71 0.02 1.16% |
Ikena Oncology financial indicator trend analysis is infinitely more than just investigating Ikena Oncology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ikena Oncology is a good investment. Please check the relationship between Ikena Oncology Capital Surpluse and its Total Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.
Capital Surpluse vs Total Liab
Capital Surpluse vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ikena Oncology Capital Surpluse account and Total Liab. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Ikena Oncology's Capital Surpluse and Total Liab is -0.64. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Total Liab in the same time period over historical financial statements of Ikena Oncology, assuming nothing else is changed. The correlation between historical values of Ikena Oncology's Capital Surpluse and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Ikena Oncology are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Capital Surpluse i.e., Ikena Oncology's Capital Surpluse and Total Liab go up and down completely randomly.
Correlation Coefficient | -0.64 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Capital Surpluse
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Ikena Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ikena Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.At present, Ikena Oncology's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.86, whereas Selling General Administrative is forecasted to decline to about 17.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 65.1M | 86.5M | 84.6M | 70.9M | Cost Of Revenue | 47.1M | 2.0M | 59.7M | 39.3M |
Ikena Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Ikena Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ikena Oncology fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 121K | 5.0M | 4.0M | 6.4M | 5.0M | 3.8M | |
| Total Current Liabilities | 24.3M | 28.3M | 27.2M | 21.5M | 14.2M | 21.9M | |
| Net Tangible Assets | (61.5M) | (101.0M) | 207.9M | 147.0M | 169.0M | 177.5M | |
| Retained Earnings | (67.1M) | (111.3M) | (145.5M) | (214.2M) | (282.4M) | (268.3M) | |
| Accounts Payable | 935K | 2.1M | 2.4M | 2.1M | 2.1M | 2.2M | |
| Other Current Assets | 1.3M | 3.5M | 4.3M | 3.1M | 3.2M | 2.9M | |
| Total Current Assets | 85.2M | 166.0M | 236.5M | 160.0M | 178.7M | 155.2M | |
| Property Plant Equipment | 769K | 1.6M | 2.4M | 3.2M | 3.7M | 1.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ikena Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ikena Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ikena Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ikena Oncology Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Revenue Per Share 0.014 | Quarterly Revenue Growth (0.88) | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.